| 12.865 0.085 (0.67%) | 04-19 15:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.13  |
1-year : | 16.9 |
| Resists | First : | 13.81 |
Second : | 14.47 |
| Pivot price | 13.71 |
|||
| Supports | First : | 12.75 |
Second : | 10.6 |
| MAs | MA(5) : | 13.11 |
MA(20) : | 13.79 |
| MA(100) : | 12.12 |
MA(250) : | 10.08 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 5.5 |
D(3) : | 8.1 |
| RSI | RSI(14): 34.5 |
|||
| 52-week | High : | 14.47 | Low : | 7.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TEVA ] has closed below the lower bollinger band by 1.9%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 39.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.3 - 13.38 | 13.38 - 13.45 |
| Low: | 12.8 - 12.89 | 12.89 - 12.99 |
| Close: | 13.04 - 13.17 | 13.17 - 13.31 |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Fri, 19 Apr 2024
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to ... - Yahoo Finance UK
Thu, 18 Apr 2024
Zacks Research Analysts Boost Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA) - MarketBeat
Wed, 17 Apr 2024
Boosted by $19M equity package, Teva's Richard Francis joins upper echelons of pharma CEO pay ranks - FiercePharma
Mon, 01 Apr 2024
Teva snares up to $150M in Abingworth funding to propel late-stage asthma rescue inhaler - FiercePharma
Mon, 11 Mar 2024
Who wants to buy Teva's API business? - Chemical & Engineering News
Tue, 20 Feb 2024
Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1,120 (M) |
| Shares Float | 1,120 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 53.1 (%) |
| Shares Short | 11,560 (K) |
| Shares Short P.Month | 14,720 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.69 |
| Profit Margin | -3.6 % |
| Operating Margin | 28 % |
| Return on Assets (ttm) | 4.5 % |
| Return on Equity (ttm) | -7.4 % |
| Qtrly Rev. Growth | 14.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 14.15 |
| EBITDA (p.s.) | 3.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,370 (M) |
| Levered Free Cash Flow | 3,290 (M) |
| PE Ratio | -25.56 |
| PEG Ratio | 3.5 |
| Price to Book value | 1.9 |
| Price to Sales | 0.9 |
| Price to Cash Flow | 10.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|